Oral pharmaceutical formulation of omarigliptin
US9937153B2 · kind B2 · utility
1Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 25, 2014 |
| Grant date | Apr 10, 2018 |
| Priority date | — |
| Expiry date | Nov 22, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.